ReviewCureus2025
ACE Inhibitors and ARBs in Chronic Kidney Disease: A Systematic Review of Randomized Controlled Trials on Albuminuria Reduction, eGFR Decline, and Safety.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Multi-Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial.Diabetes, obesity & metabolism · 2026Trial
- PLIN5 Protects Against Ang II-Induced Podocyte Lipotoxicity by Interacting With FKBP8 and Preserving Lipid Droplet-Mitochondria Contact.Cell proliferation · 2026Article
- Article
- Drug-specific risks of acute kidney injury associated with triple whammy therapy: a nationwide self-controlled case series study in Japan.Journal of pharmaceutical health care and sciences · 2026Article
- Review
- Clinical evaluation of rituximab combined with ACE inhibitors and statins in refractory nephrotic syndrome: associations with proteinuria, lipid profiles, and podocyte-related biomarkers.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article highlights the favorable renal outcomes achieved through optimized renin-angiotensin-aldosterone system (RAAS) blockade in an adult patient with chronic kidney disease (CKD) and significant proteinuria. Sustained therapy led to a marked reduction in albuminuria and stabilization of kidney function over the follow-up period, without clinically significant hyperkalemia or other adverse effects. The observation aligns with the antiproteinuric and renoprotective effects consistently reported in randomized controlled trials, while also underscoring the importance of individualized treatment adjustments to balance efficacy with safety. The clinical course supports the biological rationale that RAAS inhibition reduces intraglomerular pressure and mitigates ongoing renal injury, suggesting its continued relevance as a cornerstone in CKD management. This further emphasizes that optimal dosing, careful monitoring of electrolytes, and attention to comorbidities are key to maximizing therapeutic benefit in real-world practice, and it calls for future research to refine patient selection and long-term outcome strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.